Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cytarabine plus temozolomide versus whole-brain radiotherapy for relapsed or refractory primary central nervous system diffuse large B-cell lymphoma
ChiCTR1800014975Phase 4Recruiting
- Sponsor
- Huashan Hospital North, Fudan University
- Start
- May 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cytarabine and temozolomide in Diffuse Large B-Cell Primary Central Nervous System Lymphoma (2 arms), sponsored by Huashan Hospital North, Fudan University. Primary endpoint: Tumor burden. Started May 2018; status: recruiting.
02
Drugs
cytarabinetemozolomide
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR1800014975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014975.